NetScientific PLC (AIM:NSCI) has reported that PDS Biotechnology Corporation (NASDAQ:PDSB), a company it has invested in, has signed an exclusive global licence agreement with Merck KGaA, Darmstadt, Germany, for M9241, a tumour-targeting protein.
PDS, which is working on immunotherapies for cancer and infectious disease, will receive an upfront payment of US$5 million and be entitled to up to US$11 million in development and regulatory milestone payments, and up to US$105 million in commercial milestones, as well as a 10% royalty on future sales of M9241.
Liberum Capital expects a new drill rig to be found ‘fairly swiftly’ by Helium One Global Ltd (AIM:HE1, OTCQB:HLOGF), which earlier Tuesday revealed it had unexpectedly lost access to the kit it hoped to deploy.
“While today’s announcement is likely to result in a delay to the original 1Q23 [first-quarter] spud date, an updated timeline will be provided once a new rig has been found, Helium One remains committed to delivering a successful campaign as early as possible in 2023,” said Liberum analysts in a note to clients.
Pantheon Resources PLC (AIM:PANR, OTC:PTHRF) shares rallied as investors returned to their desks for the new year and as the explorer provided additional commentary around its Alkaid-2 well results, that had spooked the market when released on 30 December.
The explorer told investors then that the Alkaid-2 well appears to be performing well whilst still undergoing constraints of its ‘clean up’ phase, which encountered a blockage in one section of the well.
Seeing Machines Ltd (AIM:SEE, OTC:SEEMF) said it will exhibit its interior sensing technology at CES 2023, held at the Las Vegas Convention Centre, from 5 to 7 January.
According to a statement, Seeing Machines will be showcasing its latest software and algorithm developments for its FOVIO driver and occupant monitoring system (DMS/OMS) technology solutions.
Pantheon Resources PLC (AIM:PANR, OTC:PTHRF) has provided investors with further insights into last week’s Alkaid-2 well results from Alaska by publishing an ‘Investor Q&A’, via a statement on the stock exchange.
The full Q&A is shown below.
Helium One Global Ltd (AIM:HE1, OTCQB:HLOGF) said it is reviewing a number of alternative rig options for its Rukwa operation in Tanzania after it unexpectedly lost access to the Exalo drill rig that was supposed to be on-site early this year.
Chief executive David Minchin described the decision by the current operator to pay rig retention costs rather than release the unit as “disappointing and frustrating”.
San Leon Energy PLC (AIM:SLE, AQSE:SLE, OTC:SLGYF) has confirmed in a statement extensions to the deadlines for key agreements that form the proposed reorganisation of interests in the OML 18 asset – with the MLP Reorganisation and the Sahara OML 18 Acquisition Agreement both now given new deadlines of 31 March 2023, from 31 December 2022.
CentralNic Group PLC (AIM:CNIC) noted in a statement the purchase of shares in the company by Kestrel Partners LLP, a vehicle in which non-executive director Max Royde holds a beneficial interest. Kestrel purchased an additional 73,805 shares in the company across 28 and 29 December, paying an average price of £1. 489506609 per share.
Kestrel holds 17.9mln shares in CentralNic in which it is deemed that Royde has a beneficial interest in, plus a further 47.6mln shares in which he is said to have no beneficial interest. Altogether it holds some 22.7% of CentralNic.
Emmerson PLC (AIM:EML, OTC:EMSNF) has appointed Liberum Capital as its nominated advisor for its AIM listing, with immediate effect.
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) confirmed a temporary suspension to trading in its shares on the London Stock Exchange, pending publication of its audited annual results.
MetalNRG PLC (LSE:MNRG) issued a statement related to the previously announced requisition of a general meeting, and, responding to an open letter and social media posts by Mr Edward Spencer.